Advertisement

Current application of exhaled nitric oxide in clinical practice

Published:September 21, 2016DOI:https://doi.org/10.1016/j.jaci.2016.09.002
      Exhaled nitric oxide (NO) was initially used in clinical research because the analyzer was large and costly, but with the development of cheaper portable units, it is now being used in the management of asthma in specialty care settings. NO is measured in exhaled breath in parts per billion and is measured as the fraction of exhaled nitric oxide (Feno).

      Key words

      To read this article in full you will need to make a payment

      References

        • Dweik R.A.
        • Boggs P.B.
        • Erzurum S.C.
        • Irvin C.G.
        • Leigh M.W.
        • Lundberg J.O.
        • et al.
        An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FENO). for clinical applications.
        Am J Respir Crit Care Med. 2011; 184: 602-615
        • Covar R.A.
        • Spahn J.D.
        • Martin R.J.
        • Silkoff P.E.
        • Sundstrom D.A.
        • Murphy J.
        • et al.
        Safety and application of induced sputum analysis in childhood asthma.
        J Allergy Clin Immunol. 2004; 114: 578-582
        • Piacentini G.L.
        • Peroni D.G.
        • Bodini A.
        • Bonafiglia E.
        • Rigotti E.
        • Baraldi E.
        • et al.
        Childhood Asthma Control Test and airway inflammation evaluation in asthmatic children.
        Allergy. 2009; 64: 1753-1757
        • Zeiger R.S.
        • Schatz M.
        • Zhang F.
        • Crawford W.W.
        • Kaplan M.S.
        • Roth R.M.
        • et al.
        Exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids.
        J Allergy Clin Immunol. 2011; 128: 412-414
        • Silkoff P.E.
        • Lent A.M.
        • Busacker A.A.
        • Katial R.K.
        • Balzar S.
        • Strand M.
        • et al.
        Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma.
        J Allergy Clin Immunol. 2005; 116: 1249-1255
        • Dweik R.A.
        • Sorkness R.L.
        • Wenzel S.
        • Hammel J.
        • Curran-Everett D.
        • Comhair S.A.
        • et al.
        Use of nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma.
        Am J Respir Crit Care Med. 2010; 181: 1033-1041
        • Pavord I.D.
        • Korn S.
        • Howarth P.
        • Bleecker E.R.
        • Buhl R.
        • Keene O.N.
        • et al.
        Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double blind, placebo-controlled trial.
        Lancet. 2012; 380: 651-659
        • Corren J.C.
        • Lemanske R.F.
        • Hanania N.A.
        • Korenblat P.E.
        • Parsey M.V.
        • Arron J.R.
        • et al.
        Lebrikizumab treatment in adults with asthma.
        N Engl J Med. 2011; 365: 1088-1098
        • Wenzel S.
        • Ford L.
        • Pearlman D.
        • Spector S.
        • Sher L.
        • Skobieranda F.
        • et al.
        Dupilumab in persistent asthma with elevated eosinophil levels.
        N Engl J Med. 2013; 368: 2455-2466
        • Hanania N.A.
        • Wenzel S.
        • Rosen K.
        • Hsieh H.J.
        • Mosesova S.
        • Choy D.F.
        • et al.
        Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
        Am J Respir Crit Care Med. 2013; 187: 804-811

      Linked Article